4.5 Article

Prediction of overall survival in patients with hepatocellular carcinoma treated with Y-90 radioembolization by imaging response criteria

Journal

DIAGNOSTIC AND INTERVENTIONAL IMAGING
Volume 102, Issue 1, Pages 35-44

Publisher

ELSEVIER MASSON, CORP OFF
DOI: 10.1016/j.diii.2020.09.004

Keywords

Carcinoma; Hepatocellular; Yttrium radioisotopes; Embolization; Therapeutic; Response evaluation criteria in solid tumors; Survival analysis

Ask authors/readers for more resources

The study evaluated the potential of imaging criteria in predicting overall survival of HCC patients after TARE treatment. The results showed that RECIST and mRECIST were the best compromise between reproducibility and ability to predict overall survival.
Purpose: To evaluate the potential of imaging criteria in predicting overall survival of patients with hepatocellular carcinoma (HCC) after a first transcatheter arterial yttrium-90 radioembolization (TARE) Materials and methods: From October 2013 to July 2017, 37 patients with HCC were retrospectively included. There were 34 men and 3 women with a mean age of 60.5 10.2 (SD) years (range: 32.7-78.9 years). Twenty-five patients (68%) were Barcelona Clinic Liver Cancer (BCLC) C and 12 (32%) were BCLC B. Twenty-four primary index tumors (65%) were > 5 cm. Three radiologists evaluated tumor response on preand 4-7 months post-TARE magnetic resonance imaging or computed tomography examinations, using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, modified RECIST (mRECIST), European Association for Study of the Liver (EASL), volumetric RECIST (vRECIST), quantitative EASL (qEASL) and the Liver Imaging Reporting and Data System treatment response algorithm. Kaplan-Meier survival curves were used to compare responders and non-responders for each criterion. Univariate and multivariate Cox proportional hazard ratio (HR) analysis were used to identify covariates associated with overall survival. Fleiss kappa test was used to assess interobserver agreement. Results: At multivariate analysis, RECIST 1.1 (HR: 0.26; 95% confidence interval [95% CI]: 0.09-0.75; P = 0.01), mRECIST (HR: 0.22; 95% CI: 0.08-0.59; P = 0.003), EASL (HR: 0.22; 95% CI: 0.07-0.63; P = 0.005), and qEASL (HR: 0.30; 95% CI: 0.12-0.80; P = 0.02) showed a significant difference in overall survival between responders and nonresponders. RECIST 1.1 had the highest interobserver reproducibility. Conclusion: RECIST and mRECIST seem to be the best compromise between reproducibility and ability to predict overall survival in patients with HCC treated with TARE. (C) 2020 Societe francaise de radiologie. Published by Elsevier Masson SAS. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available